SEC Tracker
Get the app

bioAffinity Technologies BIAF

bioAffinity Technologies reports 100% sales growth in Q3 2026

Form
8-K
Filed
Importance
Routine
  1. CyPath Lung sales up over 100% in Q3 2026 vs. 2025
  2. Number of physician offices using CyPath Lung increased 89%
  3. Sales volume increased 48% year-over-year
  4. Over 1,620 tests delivered in Q3 2026 vs. 775 in Q3 2025

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when bioAffinity Technologies files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 8731 and related industry codes: the same peer list as the financial tables.

  1. IB Acquisition IBAC public float $15M, Mar 31, 2025, over 18 months old
  2. OneMedNet ONMD public float $14M, Jun 30, 2025
  3. 20/20 Biolabs AIDX
  4. Inotiv NOTV public float $71M, Mar 31, 2025, over 18 months old